Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy. To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
Patients with a confirmed diagnosis of gynecological malignancy;
Patients currently undergoing or scheduled to undergo immunotherapy as part of their treatment regimen;
Age > 18 years;
Patients who are able and willing to provide written informed consent to participate in the study.
Patients receiving concurrent treatment with other investigational drugs or therapies that may interfere with immunotherapy.
Presence of significant comorbidities or other medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results (e.g., severe autoimmune diseases, uncontrolled infections);
Pregnant or breastfeeding women;
Patients who have received prior monoclonal antibody therapy that could affect the study results;
Patients with gynecological cancers undergoing immunotherapy
Other
Other
Blood samples for the analysis of sildenafil in plasma
Procedure/SurgeryTo detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
Quantification of anti PD-1.
Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
